Friday, 4 September 2026European Markets

IEP INVEST Stock Was Up By 9.8% Today

Loading stream...

(VIANEWS) - The Market ended the session with IEP INVEST (IEP.BR) jumping 9.8% to €5.60 on Monday while BEL 20 rose 0.44% to €3,305.14.

IEP INVEST's last close was €5.10, 13.56% below its 52-week high of €5.90.

About IEP INVEST

Iep Invest, NV is an investment firm specializing in investments in and loans to real estate companies. The firm previously operated as manufacturing group. It was formerly known as Punch International nv and changed its name to Iep Invest, NV in May 2014. Iep Invest, NV was founded in 1982 and is based in Antwerp, Belgium.

Earnings Per Share

As for profitability, IEP INVEST has a trailing twelve months EPS of €-0.22.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -2.4%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Oct 3, 2022, the estimated forward annual dividend rate is 5 and the estimated forward annual dividend yield is 87.72%.

More news about IEP INVEST (IEP.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com